Eng-Huat Tan

3.5k total citations
34 papers, 1.3k citations indexed

About

Eng-Huat Tan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Eng-Huat Tan has authored 34 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 7 papers in Otorhinolaryngology. Recurrent topics in Eng-Huat Tan's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Eng-Huat Tan is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Eng-Huat Tan collaborates with scholars based in Singapore, United States and Taiwan. Eng-Huat Tan's co-authors include Wan‐Teck Lim, Chee‐Keong Toh, Kam-Weng Fong, Swee‐Peng Yap, Swan‐Swan Leong, Heng‐Nung Koong, Philip Eng, Thirugnanam Agasthian, Anne Ann Ling Hsu and Swan-Swan Leong and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Eng-Huat Tan

33 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eng-Huat Tan Singapore 17 772 623 329 223 196 34 1.3k
Ірина Давиденко United States 16 807 1.0× 583 0.9× 403 1.2× 196 0.9× 242 1.2× 33 1.6k
Morena Fasano Italy 20 680 0.9× 535 0.9× 605 1.8× 244 1.1× 85 0.4× 63 1.4k
Epaminontas Samantas Greece 18 857 1.1× 621 1.0× 248 0.8× 181 0.8× 153 0.8× 62 1.2k
Luciano de Souza Viana Brazil 18 492 0.6× 396 0.6× 342 1.0× 223 1.0× 225 1.1× 37 968
Zhihuang Hu China 19 1.0k 1.3× 601 1.0× 514 1.6× 387 1.7× 66 0.3× 53 1.6k
Nancy B. Davis United States 16 472 0.6× 372 0.6× 297 0.9× 175 0.8× 80 0.4× 61 989
Michael Xiang United States 16 351 0.5× 295 0.5× 475 1.4× 203 0.9× 72 0.4× 68 1.1k
Jessica Menis Italy 21 1.2k 1.5× 1.1k 1.8× 381 1.2× 363 1.6× 62 0.3× 76 1.9k
Pei-Rong Ding China 20 1.2k 1.5× 271 0.4× 195 0.6× 271 1.2× 174 0.9× 45 1.6k
Wen-Qiong Xue China 16 437 0.6× 211 0.3× 615 1.9× 415 1.9× 236 1.2× 17 1.3k

Countries citing papers authored by Eng-Huat Tan

Since Specialization
Citations

This map shows the geographic impact of Eng-Huat Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eng-Huat Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eng-Huat Tan more than expected).

Fields of papers citing papers by Eng-Huat Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eng-Huat Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eng-Huat Tan. The network helps show where Eng-Huat Tan may publish in the future.

Co-authorship network of co-authors of Eng-Huat Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Eng-Huat Tan. A scholar is included among the top collaborators of Eng-Huat Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eng-Huat Tan. Eng-Huat Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Wan‐Teck, Hsiang‐Fong Kao, Lisda Suteja, et al.. (2023). Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma. Nature Communications. 14(1). 2781–2781. 25 indexed citations
2.
Halmos, Balázs, Eng-Huat Tan, Min Ki Lee, et al.. (2018). Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm+) advanced NSCLC.. Journal of Clinical Oncology. 36(15_suppl). e21060–e21060. 5 indexed citations
3.
Mesı́a, Ricard, Paolo Bossi, Aaron R. Hansen, et al.. (2016). Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).. Journal of Clinical Oncology. 34(15_suppl). 6029–6029.
4.
Rajasekaran, Tanujaa, Quan‐Sing Ng, Daniel Shao-Weng Tan, et al.. (2016). Metronomic chemotherapy: A relook at its basis and rationale. Cancer Letters. 388. 328–333. 13 indexed citations
5.
Aix, Santiago Ponce, Keunchil Park, Eng-Huat Tan, et al.. (2016). P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial. Journal of Thoracic Oncology. 11(10). S203–S204. 1 indexed citations
6.
Tan, Eng-Huat, Wan‐Teck Lim, Quan‐Sing Ng, et al.. (2016). Advances in systemic treatment for nasopharyngeal carcinoma. Chinese Clinical Oncology. 5(2). 21–21. 65 indexed citations
7.
Jain, Amit, Angela Takano, Evan W. Newell, et al.. (2016). Novel therapeutic targets on the horizon for lung cancer. The Lancet Oncology. 17(8). e347–e362. 141 indexed citations
8.
Tan, Daniel S.W., Quan‐Sing Ng, Sai Sakktee Krisna, et al.. (2013). Molecular Profiling for Druggable Genetic Abnormalities in Carcinoma of Unknown Primary. Journal of Clinical Oncology. 31(14). e237–e239. 26 indexed citations
9.
Teo, Marissa, Who-Whong Wang, Bernett Lee, et al.. (2013). Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma. Molecular Therapy. 22(1). 132–139. 178 indexed citations
10.
Ang, Mei‐Kim, Minn Minn Myint Thu, Wai Meng David Tai, et al.. (2012). Association of smoking status with p16 and cyclin D1 (CCND1) expression with clinical characteristics and overall survival (OS) in oropharyngeal squamous cell carcinoma (OSC).. Journal of Clinical Oncology. 30(15_suppl). 5551–5551. 2 indexed citations
11.
12.
Reck, Martin, Andreas Hermes, Eng-Huat Tan, et al.. (2011). Tissue sampling in lung cancer: A review in light of the MERIT experience. Lung Cancer. 74(1). 1–6. 28 indexed citations
13.
Choo, Su Pin, Wan‐Teck Lim, Chee‐Keong Toh, et al.. (2009). Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis. Journal of Thoracic Oncology. 4(8). 988–993. 4 indexed citations
14.
Yap, Swee‐Peng, Wan‐Teck Lim, Siew Wan Hee, et al.. (2008). Induction Concurrent Chemoradiotherapy Using Paclitaxel and CarboplatinCombination Followed by Surgery in Locoregionally Advanced Non-Small Cell Lung Cancer – Asian Experience. Annals of the Academy of Medicine Singapore. 37(5). 377–382. 7 indexed citations
15.
Toh, Chee‐Keong, Siew Wan Hee, Wan‐Teck Lim, et al.. (2007). Survival of Small-cell Lung Cancer and its Determinants of Outcome in Singapore. Annals of the Academy of Medicine Singapore. 36(3). 181–188. 6 indexed citations
16.
Tan, Eng-Huat, Rodryg Ramlau, A Płużańska, et al.. (2007). D2-04: MERIT: a prospective study of putative relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S394–S395. 5 indexed citations
17.
18.
Toh, Chee‐Keong, Fei Gao, Wan‐Teck Lim, et al.. (2007). Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. Lung Cancer. 56(2). 161–166. 22 indexed citations
19.
Toh, Chee‐Keong, Fei Gao, Wan‐Teck Lim, et al.. (2006). Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity. Journal of Clinical Oncology. 24(15). 2245–2251. 301 indexed citations
20.
Adelstein, David J., Eng-Huat Tan, & Pierre Lavertu. (1996). Treatment of head and neck cancer: the role of chemotherapy. Critical Reviews in Oncology/Hematology. 24(2). 97–116. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ірина Давиденко Breakdown of academic impact, for papers by Morena Fasano Breakdown of academic impact, for papers by Epaminontas Samantas Breakdown of academic impact, for papers by Luciano de Souza Viana Breakdown of academic impact, for papers by Zhihuang Hu Breakdown of academic impact, for papers by Nancy B. Davis Breakdown of academic impact, for papers by Michael Xiang Breakdown of academic impact, for papers by Jessica Menis Breakdown of academic impact, for papers by Pei-Rong Ding Breakdown of academic impact, for papers by Wen-Qiong Xue
Rankless by CCL
2026